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Abstract
Objectives To compare plasma levodopa concentrations
after repeated doses of levodopa/carbidopa/entacapone
(LCE) and levodopa/carbidopa (LC).
Methods Open-label, randomized, two-period, active-
controlled, cross-over study with four dosing regimens:
groups I and II (healthy volunteers and Parkinson’s disease
patients) received levodopa 100 mg or 150 mg four times
daily, respectively, and groups III and IV (healthy volunteers)
received the same strengths of levodopa five times daily.
Pharmacokinetic (PK) parameters determined for levodopa
included Cmin, Cmax, Cmax−Cmin, AUC, t1/2, and tmax.
Results In healthy volunteers and PD patients, mean trough
levels (Cmin), Cmax, and AUC of levodopa were, in general,
significantly higher during LCE compared to LC adminis-
tration. Compared to Cmin, Cmax, and AUC, differences
between the treatments in variability of levodopa concen-
trations (Cmax−Cmin) were less consistent.
Conclusions The present results on the differences in
levodopa PK between LCE and LC provide a basis to
evaluate the relationship of levodopa PK and the
induction of motor complications in an on-going
study in early Parkinson’s disease using similar dosing
regimens.
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Introduction
The motor symptoms of Parkinson’s disease (PD) are
mainly due to the loss of dopaminergic innervation of the
striatum. Therefore, the most successful treatment strategies
are those that replenish striatal dopamine levels or mimic
the action of dopamine.
Levodopa is still the most effective treatment for the
symptoms of PD. Levodopa is metabolized mainly by
two enzymes, dopa decarboxylase (DDC) and catechol
O-methyltransferase (COMT). Levodopa is nowadays
always combined with a DDC inhibitor (DDCI; carbi-
dopa or benserazide), which improves the delivery of
levodopa to the brain. However, blocking DDC shifts the
peripheral metabolism of levodopa towards COMT, with
O-methylation becoming the prominent metabolic path-
way [1]. Therefore, oral levodopa therapy can be further
improved by COMT-inhibitors.
Entacapone is a selective, reversible, peripherally acting
COMT-inhibitor [2]. The pharmacokinetic (PK) profiles of
entacapone and levodopa are comparable and the time
course of COMT inhibition by entacapone also follows the
plasma-concentration-time curve (AUC) of entacapone [2].
Therefore, entacapone is always taken together with each
dose of levodopa/DDCI. Tolcapone is another clinically
available COMT-inhibitor [3] that is taken three times daily
(t.i.d) regardless of the dosing frequency of levodopa/
DDCI. Oral levodopa therapy with levodopa/DDCI and
entacapone or tolcapone is associated with an improved
levodopa plasma profile (increased AUC and elimination
half-life) and prolonged therapeutic response in patients
with PD [4–6]. This improved pharmacokinetic profile of
levodopa has been shown to translate into decreased “off-
time” and increased “on-time” in PD patients with wearing-
off symptoms [7–10]. Both COMT-inhibitors also improve
levodopa’s effects in the symptomatic treatment of early PD
patients [11–12].
The current concept of continuous dopaminergic stimu-
lation (CDS) suggests that a more stable plasma concen-
tration of a given dopaminergic drug will result in a
prolonged response to treatment. Additionally, it has been
postulated that pulsatile stimulation of striatal post-synaptic
dopamine receptors may lead to a series of molecular and
physiological changes that are thought to underlie the
development of motor complications, such as dyskinesia
and wearing-off [13]. In particular, studies with continuous
enteral infusion of levodopa indicate that maintaining
plasma levodopa concentrations above a minimum anti-
parkinsonian threshold by avoiding low trough concen-
trations may be a key factor in optimizing treatment
response and reducing motor complications [14–15].
Interestingly, these benefits seem to be independent of
maximum levodopa concentrations (Cmax) and some fluc-
tuation in plasma levels [15].
Whether the improved levodopa plasma profile seen
with COMT-inhibitors can reduce motor complications has
so far been studied in treatment-naive N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) primates, a widely
recognized animal model for PD. Smith et al. [16] have
shown that treatment of MPTP-treated primates with four
daily doses of levodopa/carbidopa (LC) and entacapone
was equally effective, but produced less dyskinesia com-
pared with those treated with an equivalent daily-dosing
regimen of LC alone. Based on the CDS concept and the
results reported by Smith et al. [16], a large, international,
double-blind, randomized study is currently on-going in
patients with early PD without motor complications who
require the initiation of levodopa therapy [17]. The
hypothesis of this study is that frequent dosing of
levodopa/carbidopa/entacapone (LCE) will delay the onset
of dyskinesia compared to treatment with equivalent doses
of LC. The two main maintenance-dose levels in this study
are LCE 100/25/200 mg or 150/37.5/200 mg, or equivalent
doses of LC administered four times daily at 3.5-h intervals.
If the hypothesis of this study holds true, it will be very
important to determine which differences in the daily PK
profiles of LCE and LC translate into a reduced risk of
motor complications during long-term therapy. For this
purpose, a study divided into two parts, the first part
conducted in healthy volunteers and the other in PD
patients, was designed to compare the PK profile of
levodopa during treatment with LCE and LC with the
above-mentioned treatment regimens. We also studied
levodopa plasma profiles in healthy volunteers receiving
five daily doses of LCE and LC to see whether more
frequent dosing would make any further difference between
the two treatments.
Materials and methods
Study design and treatments
The study was conducted in two parts. Part 1 was an open-
label, randomized, active-controlled, two-period, cross-over
PK study conducted in healthy volunteers. Subjects were
enrolled into one of four dosing groups. Group I received
100 mg levodopa, four times daily every 3.5 h; group II
150 mg levodopa, four times daily every 3.5 h; group III
100 mg levodopa, five times daily every 3.0 h; and group
IV 150 mg levodopa, five times daily every 3.0 h. Each
parallel group had a cross-over design with their respective
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LCE and LC strengths. Part 2 was conducted in PD patients
and was identical in design to part 1 with groups I and II as
described above. The study part conducted in PD patients
has been registered at http://www.clinicaltrials.gov/ (study
code NCT00693862).
The study medication consisted of LCE 100 or LCE 150
(levodopa/carbidopa/entacapone, 100/25/200 mg or 150/37.5/
200 mg tablets, respectively; Stalevo, Orion Corporation
Orion Pharma, Espoo, Finland), and LC 100 or LC 150
(levodopa/carbidopa, 100/25 mg tablet or one 100/25 mg
tablet given together with one 50/12.5 mg tablet, respectively;
Sinemet, Merck, Sharp & Dohme, Haarlem, the Netherlands).
In each group (I–IV) of part 1, subjects were randomized
to receive either LCE or LC during period 1 and then
subsequently crossed over to the other drug in period 2.
Study drug was up-titrated during the first treatment period
due to the moderate daily levodopa doses used and to avoid
possible adverse events (AEs), such as nausea. Between
periods 1 and 2, there was no wash-out period to avoid the
need for re-titration. Period 1 lasted for 4–7 days and period
2 lasted for 3 days. The length of the titration period was the
same for all subjects within each treatment group. In part 2
conducted in PD patients, the appropriate study group for
each subject was selected by the investigator according to the
subject’s daily levodopa dose prior to the randomization.
There was a wash-out period of 3–7 days between the
treatment periods during which time the subjects continued
on their individual daily levodopa treatment.
Both healthy volunteers and patients with PD fasted from
10:00 PM, but water was allowed up to 1 h before the first
morning dose and subsequent PK assessment. All study
treatment doses were ingested with 200 mL of water and the
first morning dose was taken at approximately 08:00 AM. The
timing of food intake was standardized to avoid differences
between the two periods in each group in this respect.
Breakfast, lunch, dinner, and a light evening meal were served
1 h after each dose and a snack was given either 1 h before
the third dose (groups I and II in healthy volunteers and PD
patients with four daily doses) or 1 h after the third dose
(groups III and IV in healthy volunteers with five daily doses).
Each dosing group had a standard 2×2 cross-over design
and a block size of two was chosen for the randomization
process. Since the study was open, no blinding was applied.
The study was performed according to good clinical
practice, reviewed by the local ethics committee, and
approved by the Finnish national competent authority. All
subjects gave their written informed consent.
Study population
Part 1 of the study was conducted in healthy male and
female volunteers. Exclusion criteria included any condi-
tion requiring regular concomitant medication (except
contraceptives or hormone replacement therapy) or other
medication that could have affected the outcome of the
study. PD patients (male or female) in part 2 had to be on
three to five daily doses of levodopa/DDCI ± entacapone
with a total daily levodopa dose in the range of 300–
600 mg. One or more doses of controlled-release levodopa/
DDCI preparations were allowed providing that they were
included in the total of three to five daily doses mentioned
above. These requirements regarding prior levodopa treat-
ment were selected to ensure that patients could switch
smoothly to their study dosing regimen. Levodopa/DDCI ±
entacapone and other antiparkinsonian medications (dopa-
mine agonists, MAO-B inhibitor, amantadine, and/or anti-
cholinergics) were to be kept unchanged for at least
2 weeks prior to the first treatment period.
Blood sampling and determination of levodopa, carbidopa,
and entacapone concentrations
Venous blood samples for the determination of levodopa and
carbidopa levels were collected on PK assessment days prior
to the morning dose and subsequently at 0.5- or 1-h intervals
up to 16 h (groups I and II) or up to 17 h (groups III and IV
in healthy volunteers). An additional blood sample was
collected for subjects who received LCE prior to LC to
ensure that no detectable levels of entacapone were present
before the first dose of LC was administered on the day of
the PK assessment for period 2. Plasma samples for
levodopa and carbidopa analysis were stored with an
antioxidant at –70˚C and samples for entacapone analysis
at –20˚C.
Determination of carbidopa and levodopa in human
plasma was carried out using HPLC method with EC
detection. The sample preparation involved solid-phase
extraction of plasma (0.5 mL) on RECIPE Clin Rep
cartridges. Samples were stabilized with sodium pyrosul-
phite. The determination of the analytes was carried out within
the calibration range of 2.5 ng/mL (LLOQ, lower limit of
quantification) to 500 ng/mL (ULOQ, upper limit of quantifi-
cation) for carbidopa and 25 ng/mL (LLOQ) to 5,000 ng/mL
(ULOQ) for levodopa. During the study, the inter-assay
accuracy, indicated by bias, was between -3.6 and 0.0% for
carbidopa and 2.7 and 4.2% for levodopa; the precision,
indicated by the coefficient of variation, was between 5.5 and
6.6% for carbidopa and 3.7 and 5.1% for levodopa.
Determination of entacapone in human plasma was carried
out using the LC-MS/MS method. The sample preparation
involved solid-phase extraction of plasma (0.25 mL) on
Isolute MFC18 cartridges; D10-entacapone was used as
internal standard. The analytical procedure was linear from
10.0 (LLOQ) to 1,000 (ULOQ) ng/mL. During the study (all
determinations were done in one batch) the intra-assay
inaccuracy was ±3% and the intra-assay imprecision <4%.
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Pharmacokinetic analysis
A noncompartmental method was used to calculate the PK
parameters of levodopa after each dose. PK parameters of
levodopa included minimum observed concentration (Cmin),
maximum observed concentration (Cmax), area under the
curve calculated with the linear trapezoidal rule for each dose
interval (AUCtau), time to reach the maximum observed
concentration (tmax), and terminal elimination half-life (t1/2)
after the last dose. Additionally, the means of the above PK
parameters (except t1/2 and tmax) throughout the day and
AUC0–14 or AUC0–15 (depending on the group) were also
determined. Variability of levodopa plasma concentration
during the day (fluctuation) was calculated by Cmax−Cmin
(and not, for example, by the peak-through-fluctuation
formula) because day-time variability was assessed after
repeated doses during 1 day of study drug administration,
and steady-state conditions were not reached. The PK
parameters of interest for carbidopa were AUCtau for each
dose interval, as well as AUC0–14 or AUC0–15.
Safety
Twelve-lead electrocardiogram (ECG), vital signs (systolic and
diastolic blood pressure and heart rate), physical examination
and routine laboratory safety parameters were used to monitor
safety in each subject. Data on AEs were collected throughout
the study and were classified according to version 9.1 of the
Medical Dictionary for Regulatory Activities coding system.
Statistical analysis
The sample-size calculation was based on a previous study
with four daily doses of controlled-release LC 100/25 mg
and entacapone 200 mg given at 4-h intervals [18]. The
sample size needed to produce a statistical power of 80% in
this study was nine subjects (with a significance level of
5%). As there were no within-subject variance data
available, this estimate was considered to be sufficient for
a cross-over study. It was, therefore, decided to include 10
subjects in each study group.
The analyses of the primary and secondary variables were
based on a comparison of all values after each levodopa dose
between the LCE and LC treatments. All analyses were
performed separately for each group. These variables were
evaluated using analysis of variance for cross-over design,
which included repeated measurements within the study
periods. The statistical model included treatment, sequence,
period, time, sequence × time, period × time, and treatment ×
time as fixed effects, and subject within sequence, period ×
subject within sequence, and time × subject within sequence
as random effects (Wallenstein-Fisher model [19]). Values for
AUC0–14 (or AUC0–15) and t1/2 were also compared using
analysis of variance for cross-over design and included
treatment, sequence, and period as fixed effects, and subject
within sequence as the random effect. These analyses were
performed separately for each group.
In all analyses, Cmin, AUCtau, Cmax, Cmax−Cmin, and
AUC0–14 (or AUC0–15) were analyzed after logarithmic
transformation to achieve normality assumption. Analyses
of PK variables included all subjects participating in the
study and providing calculable data from one or both
periods. All tests were two-sided and used a 5% signifi-
cance level. The 95% confidence intervals were calculated
for the ratio of the geometric means within statistical
models. No multiplicity corrections were made in the
statistical analyses. All analyses were programmed with
SAS 9.1.3 for Windows (SAS Institute, Cary, NC, USA).
Results
Study population
In part 1, a total of 53 healthy subjects were screened; of these,
41 subjects (33 women and 8 men) were enrolled and 37
subjects completed the study. The mean age of the 41 enrolled
healthy subjects was 23.7 (range: 18–37) years, mean weight
was 63 (50–85) kg, and mean body mass index (BMI) was
21.9 (19–27) kg/m2. No subject had any medical condition or
was taking any concomitant medication that could have
interfered with the interpretation of the results. In part 2, a
total of 23 PD patients were screened, and 19 patients were
enrolled, all completing the study. The mean age of the PD
patients was 63.3 (range 57–71) years, mean weight was 81.7
(56–103) kg, and mean BMI was 28.2 (22–34) kg/m2. Mean
duration of PD was 6.7 (range 0.4–14.1) years, and mean
duration of levodopa treatment was 6.2 (0.4–13.3) years. In
group I (n=10), two patients had wearing-off symptoms and
eight had stable disease. In group II (n=9), six patients had
wearing-off symptoms, and three had stable disease.
Pharmacokinetic results
Levodopa
Cmin in healthy volunteers In all four dosing groups, the
geometric means of all Cmin values from 0–14 h (0–15 h in
groups III and IV) were significantly higher (by 78–105%,
all P<0.0001) with LCE compared with LC treatment (Fig. 1
and Table 1). The Cmin values after each LCE dose were also
significantly higher (P<0.0001) when compared with Cmin
values after the respective LC dose (Fig. 1 and Table 2).
Time × treatment interaction was statistically significant (P<
0.001) in group IV, i.e., the differences in mean Cmin values
between the treatments increased towards the end of the day.
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Cmin in PD patients In groups I and II, the geometric means
of all Cmin values from 0–14 h were significantly higher (by
89–100%, both P<0.0001) with LCE compared with LC
treatment. The Cmin values after each LCE dose were also
significantly higher (P<0.0001) when compared with Cmin
values after the respective LC dose (Fig. 1).
Cmax in health volunteers The mean of all Cmax values from
0–14 h (0–15 h for groups III and IV) was significantly
higher (by 17–27%) in all groups (P<0.05) after LCE
treatment compared with LC treatment (Tables 1 and 3). In
group I, the ratio between the treatments changed from the
first dose to the later doses of the day, showing significant
(P<0.05) treatment × time interaction (Table 4).
Cmax in PD patients The mean of all Cmax values from 0–
14 h in group I was 8% higher during LCE treatment
compared to LC, the difference being statistically nonsig-
nificant (Table 3, P=0.17). The difference remained non-
significant also for each dosing interval (Table 4). In group
Fig. 1 Levodopa Cmin (mean ± SD, ng/ml) after each dose in healthy volunteers and patients with PD (groups I–II)
Table 1 Mean levodopa Cmin (ng/ml), Cmax (ng/ml), variability in levodopa concentrations as assessed by Cmax−Cmin (ng/ml) and AUC0–15
(h·µg/ml) during the entire day in healthy volunteers (groups III–IV)
LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Group III: 100 mg × 5, 3-h interval,
LCE n=8, LC n=9
Mean Cmin 901 (386) 445 (201) 2.05 <0.0001
b
Mean Cmax 1,760 (509) 1,550 (535) 1.17 <0.05
b
Mean Cmax−Cmin 888 (408) 1,110 (556) 0.84 0.24b
AUC0–15 17,300 (3,780) 12,400 (2,350) 1.42 <0.0001
Group IV: 150 mg × 5, 3-h interval,
LCE n=7, LC n=8
Mean Cmin 1,580 (654) 798 (224) 1.84 <0.001
b
Mean Cmax 2,770 (915) 2,210 (773) 1.27 <0.05
b
Mean Cmax−Cmin 1,270 (894) 1,420 (808) 0.85 0.45b
AUC0–15 28,300 (4,340) 19,400 (2,380) 1.46 <0.001
Cmin Minimum levodopa concentration, Cmax maximum levodopa concentration, Cmax−Cmin fluctuation in levodopa concentration, AUC area
under the curve, LCE levodopa/carbidopa/entacapone, LC levodopa/carbidopa, PD Parkinson’s disease, SD standard deviation
a Ratio for estimates of geometric means
bP value was obtained by analyzing all individual values during 0–15 h
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Table 2 Pharmacokinetic parameters of levodopa [Cmin (ng/ml), Cmax (ng/ml), variability in levodopa concentrations as assessed by Cmax−Cmin
(ng/ml), AUC0–15 and AUCtau (h·μg/mL)] after each dose in healthy volunteers (groups III–IV)
Dosing group and regimen LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Cmin (ng/ml) Group III: 100 mg × 5,
3-h interval,
LCE n=8, LC n=9
Mean 901 (386) 445 (201) 2.05 <0.0001b
Cmin (dose 1) 525 (164) 257 (68.9) 2.06 <0.0001
Cmin (dose 2) 909 (387) 442 (175) 2.05 <0.0001
Cmin (dose 3) 931 (320) 538 (194) 1.75 <0.0001
Cmin (dose 4) 1,050 (350) 497 (162) 2.09 <0.0001
Cmin (dose 5)
c 1,090 (446) 493 (259) 2.33 <0.0001
Group IV: 100 mg × 5,
3-h interval,
LCE n=7, LC n=8
Mean 1,580 (654) 798 (224) 1.84 <0.001b
Cmin (dose 1) 766 (150) 484 (97.8) 1.46 <0.001
Cmin (dose 2) 1,300 (200) 836 (209) 1.56 <0.0001
Cmin (dose 3) 1,470 (300) 844 (144) 1.69 <0.0001
Cmin (dose 4) 1,980 (556) 938 (209) 2.12 <0.0001
Cmin (dose 5)
c 2,360 (429) 890 (117) 2.57 <0.0001
Cmax (ng/ml) Group III: 100 mg × 5,
3-h interval,
LCE n=8, LC n=9
Mean 1,760 (509) 1,550 (535) 1.17 <0.05b
Cmax (dose 1) 1,250 (279) 1,500 (732) 0.93 0.56
Cmax (dose 2) 2,110 (395) 1,560 (399) 1.37 0.012
Cmax (dose 3) 1,680 (266) 1,290 (506) 1.41 <0.01
Cmax (dose 4) 2,020 (735) 1,800 (538) 1.12 0.36
Cmax (dose 5) 1,730 (270) 1,610 (427) 1.11 0.37
Group IV: 150 mg × 5,
3-h interval,
LCE n=7, LC n=8
Mean 2,770 (915) 2,210 (773) 1.27 <0.05b
Cmax (dose 1) 2,250 (560) 1,760 (568) 1.32 0.10
Cmax (dose 2) 3,100 (1,190) 2,580 (777) 1.22 0.23
Cmax (dose 3) 2,070 (295) 2,110 (807) 1.04 0.83
Cmax (dose 4) 3,110 (915) 2,590 (645) 1.18 0.33
Cmax (dose 5) 3,310 (785) 2,040 (855) 1.70 <0.01
Cmax−Cmin (ng/ml) Group III: 100 mg × 5,
3-h interval,
LCE n=8, LC n=9
Mean 888 (408) 1,110 (556) 0.84 0.24
Cmax−Cmin (dose 1) 747 (337) 1,250 (745) 0.62 0.09
Cmax−Cmin (dose 2) 1,240 (342) 1,120 (469) 1.18 0.57
Cmax−Cmin (dose 3) 823 (282) 754 (434) 1.33 0.31
Cmax−Cmin (dose 4) 969 (512) 1,300 (429) 0.73 0.27
Cmax−Cmin (dose 5) 642 (347) 1,110 (589) 0.60 0.08
Group IV: 150 mg × 5,
3-h interval,
LCE n=7, LC n=8
Mean 1,270 (894) 1,420 (808) 0.85 0.45
Cmax−Cmin (dose 1) 1,590 (501) 1,270 (642) 1.37 0.38
Cmax−Cmin (dose 2) 2,010 (1150) 1,740 (911) 1.15 0.71
Cmax−Cmin (dose 3) 627 (314) 1,260 (900) 0.63 0.22
Cmax−Cmin (dose 4) 1,110 (1,030) 1,650 (702) 0.46 <0.05
Cmax−Cmin (dose 5) 949 (593) 1,150 (882) 0.98 0.97
AUC (h·μg/ml) Group III: 100 mg × 5,
3-h interval,
LCE n=8, LCE n=9
AUC0–15 17,300 (3,780) 12,400 (2,350) 1.42 <0.0001
AUCtau (dose 1) 2,000 (477) 1,910 (646) 1.12 0.15
AUCtau (dose 2) 3,490 (646) 2,320 (457) 1.53 <0.0001
AUCtau (dose 3) 3,730 (971) 2,430 (826) 1.61 <0.0001
AUCtau (dose 4) 4,040 (1,300) 2,960 (803) 1.37 <0.001
AUCtau (dose 5) 4,000 (888) 2,740 (264) 1.46 <0.0001
Group IV: 150 mg × 5,
3-h interval,
LCE n=7, LCE n=8
AUC0–15 28,300 (4,340) 19,400 (2,380) 1.46 <0.001
AUCtau (dose 1) 3,770 (610) 2,990 (613) 1.29 <0.05
AUCtau (dose 2) 5,110 (1,220) 3,730 (545) 1.36 <0.05
AUCtau (dose 3) 4,690 (377) 4,010 (998) 1.15 0.23
AUCtau (dose 4) 6,730 (1,270) 4,560 (658) 1.47 <0.001
AUCtau (dose 5) 7,790 (1,790) 4,220 (1080) 1.88 <0.0001
Cmin Minimum levodopa concentration, Cmax maximum levodopa concentration, Cmax – Cmin fluctuation in levodopa concentration, AUC area
under the curve, LCE levodopa/carbidopa/entacapone, LC levodopa/carbidopa, SD standard deviation
a Ratio for estimates of geometric means
bP value was obtained by analyzing all individual values during 0–14 h
c Concentration measured at 15 h
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Table 3 Mean levodopa Cmax (ng/ml), variability in levodopa concentrations as assessed by Cmax−Cmin (ng/ml) and AUC0–14 (h·µg/ml) during
the entire day in healthy volunteers and patients with PD (groups I–II)
Dosing group and regimen LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Healthy volunteers Group I: 100 mg × 4,
3.5-h interval,
LCE n=9, LC n=10
Cmax 1,520 (515) 1,260 (413) 1.17 <0.01
b
Cmax−Cmin 949 (546) 949 (423) 0.89 0.24b
AUC0–14 12,300 (2,190) 9,100 (945) 1.34 <0.0001
Group II: 150 mg × 4,
3.5-h interval,
LCE n=10, LC n=10
Cmax 2,370 (769) 1,960 (654) 1.21 <0.05
b
Cmax−Cmin 1,420 (787) 1,460 (684) 0.92 0.51b
AUC0–14 20,300 (767) 15,300 (2,700) 1.32 <0.001
Patients with PD Group I: 100 mg × 4,
3.5-h interval,
LCE n=10, LC n=10
Cmax 1,410 (313) 1,280 (209) 1.08 0.17
b
Cmax−Cmin 824 (210) 978 (156) 0.82 <0.05b
AUC0–14 12,000 (2,920) 8,840 (1,870) 1.32 <0.0001
Group II: 150 mg × 4,
3.5-h interval,
LCE n=9, LC n=9
Cmax 2,380 (825) 2,010 (644) 1.19 <0.01
b
Cmax−Cmin 1,350 (634) 1,490 (580) 0.92 0.48b
AUC0–14 19,900 (6,950) 14,100 (4,880) 1.39 <0.0001
Cmin Minimum levodopa concentration, Cmax maximum levodopa concentration, Cmax−Cmin fluctuation in levodopa concentration, AUC area
under the curve, LCE levodopa/carbidopa/entacapone, LC levodopa/carbidopa, SD standard deviation, PD Parkinson’s disease
a Ratio for estimates of geometric means
bP value was obtained by analyzing all individual values during 0–14 h
Table 4 Levodopa Cmax (ng/ml) during the entire day and after each dose in healthy volunteers and patients with PD (groups I-II)
Dosing group and regimen LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Healthy volunteers Group I: 100 mg × 4,
3.5-h interval,
LCE n=9, LC n=10
Mean Cmax 1,520 (515) 1,260 (413) 1.17 <0.01
b
Cmax (dose 1) 1,120 (406) 1,180 (356) 0.92 0.41
Cmax (dose 2) 1,930 (556) 1,340 (595) 1.49 <0.001
Cmax (dose 3) 1,560 (431) 1,270 (327) 1.20 0.10
Cmax (dose 4) 1,450 (338) 1,240 (366) 1.16 0.17
Group II: 150 mg × 4,
3.5-h interval,
LCE n=10, LC n=10
Mean Cmax 2,370 (769) 1,960 (654) 1.21 <0.05
b
Cmax (dose 1) 1,760 (356) 1,840 (839) 1.02 0.82
Cmax (dose 2) 3,050 (764) 2,330 (574) 1.32 <0.05
Cmax (dose 3) 2,360 (617) 1,840 (498) 1.29 <0.05
Cmax (dose 4) 2,300 (730) 1,850 (614) 1.23 0.07
Patients with PD Group I: 100 mg × 4,
3.5-h interval,
LCE n=10, LC n=10
Mean Cmax 1,410 (313) 1,280 (209) 1.08 0.17
b
Cmax (dose 1) 1,130 (247) 1,160 (327) 1.00 0.97
Cmax (dose 2) 1,400 (275) 1,270 (360) 1.12 0.22
Cmax (dose 3) 1,480 (613) 1,360 (268) 1.03 0.72
Cmax (dose 4) 1,640 (484) 1,340 (258) 1.20 0.05
Group II: 150 mg × 4,
3.5-h interval,
LCE n=9, LC n=9
Mean Cmax 2,380 (825) 2,010 (644) 1.19 <0.01
b
Cmax (dose 1) 1,920 (870) 1,850 (1,040) 1.07 0.51
Cmax (dose 2) 2,450 (837) 2,400 (469) 0.98 0.81
Cmax (dose 3) 2,500 (1,030) 1,810 (708) 1.40 <0.01
Cmax (dose 4) 2,650 (756) 1,980 (767) 1.38 <0.01
Cmax Maximum levodopa concentration, LCE levodopa/carbidopa/entacapone, LC levodopa/carbidopa, SD standard deviation, PD Parkinson’s
disease
a Ratio for estimates of geometric means
bP value was obtained by analyzing all individual values during 0–14 h
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II, the mean of all Cmax values from 0–14 h was 19% higher
during LCE treatment compared to LC (Table 3, P<0.01).
However, when the difference was analyzed separately for
each dosing interval, it was statistically significant only
after the third and fourth dose due to significant treatment ×
time interaction (Table 4, P<0.05).
AUCtau and AUC0–14 and AUC0–15 in healthy volunteers In
all groups, AUC0–14 and AUC0–15 values were significantly
(P<0.001) higher (by 34–46%) following LCE treatment
compared with LC treatment (Tables 1 and 3). Similarly,
AUCtau values for each dosing interval were generally
significantly higher (P<0.05) with two exceptions: after the
first dose in group III and after the third dose in group IV
(Table 2). Values for AUCtau increased towards the end of
the day with both LCE and LC (the increase being greater
with LCE) resulting in a significant treatment × time
interaction (P<0.05) in groups I, III, and IV (Tables 2 and 5).
AUCtau and AUC0–14 and AUC0–15 in PD patients The
AUC0–14 values in groups I and II were significantly (P<
0.0001) higher (by 32–39%) following LCE compared to
LC (Table 3). Similarly, AUCtau values for each dosing
interval in both groups were significantly higher following
LCE (Table 5). The only exception was the first dosing
interval (P=0.06) in group II, in which treatment × time
interaction was statistically significant (P<0.01).
Variability of levodopa plasma concentrations, Cmax−Cmin,
in healthy volunteers The variability of levodopa plasma
concentrations (Cmax−Cmin) during the day was slightly
smaller (by 8–16%) during LCE treatment in all four
groups (Table 1 and 3). However, the difference did not
reach statistical difference in any of the groups. Cmax−
Cmin values of levodopa between the treatments did not
reach statistical significance during any of the individual
dosing intervals in groups I, II, and III (Tables 2 and 6). In
group IV, Cmax−Cmin of levodopa during LCE was
significantly lower (P<0.05) during the fourth dose of
the day (Table 2).
Variability of levodopa plasma concentrations, Cmax−Cmin,
in PD patients In group I, the mean variability (Cmax−
Cmin) during the day (0–14 h) was statistically significantly
lower (by 18%, P<0.05) during LCE compared to LC
(Table 3). For separate dosing intervals, the difference was
statistically significant favoring LCE only after the third
dose (Table 6, P<0.05). In contrast, there was no difference
in the mean variability of levodopa plasma concentrations
between the treatments in group II (Tables 3 and 6).
Table 5 Levodopa AUC0–14 and AUCtau (h·μg/mL) after each dose in healthy volunteers and patients with PD (groups I-II)
Dosing group and regimen LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Healthy volunteers Group I: 100 mg × 4,
3.5-h interval, LCE n=9,
LC n=10
AUC0–14 12,300 (2,190) 9,100 (945) 1.34 <0.0001
AUCtau (dose 1) 2,200 (703) 1,930 (588) 1.12 <0.05
AUCtau (dose 2) 3,140 (523) 2,320 (605) 1.37 <0.0001
AUCtau (dose 3) 3,200 (732) 2,320 (377) 1.35 <0.0001
AUCtau (dose 4) 3,590 (1,040) 2,550 (644) 1.36 <0.0001
Group II: 150 mg × 4,
3.5-h interval, LCE n=10,
LC n=10
AUC0–14 20,300 (767) 15,300 (2,700) 1.32 <0.001
AUCtau (dose 1) 3,420 (767) 2,860 (734) 1.20 <0.05
AUCtau (dose 2) 5,330 (251) 4,050 (748) 1.31 <0.01
AUCtau (dose 3) 5,100 (322) 3,760 (718) 1.34 <0.01
AUCtau (dose 4) 5,480 (811) 4,060 (882) 1.30 <0.01
Patients with PD Group I: 100 mg × 4,
3.5-h interval, LCE n=10,
LC n=10
AUC0–14 12,000 (2,920) 8,840 (1,870) 1.32 <0.0001
AUCtau (dose 1) 2,060 (471) 1,810 (400) 1.14 <0.05
AUCtau (dose 2) 2,940 (768) 2,270 (623) 1.30 <0.0001
AUCtau (dose 3) 3,190 (1,040) 2,320 (462) 1.34 <0.0001
AUCtau (dose 4) 3,810 (1,110) 2,440 (504) 1.53 <0.0001
Group II: 150 mg × 4,
3.5-h interval, LCE n=9,
LC n=9
AUC0–14 19,900 (6,950) 14,100 (4,880) 1.39 <0.0001
AUCtau (dose 1) 3,360 (1,420) 2,870 (1,110) 1.15 0.06
AUCtau (dose 2) 4,950 (1,680) 3,750 (1,140) 1.31 <0.001
AUCtau (dose 3) 5,380 (2,200) 3,360 (1,190) 1.58 <0.0001
AUCtau (dose 4) 6,230 (1,960) 4,070 (1,700) 1.57 <0.0001
LCE Levodopa/carbidopa/entacapone, LC levodopa/carbidopa, SD standard deviation, PD Parkinson’s disease
a Ratio for estimates of geometric means
450 Eur J Clin Pharmacol (2009) 65:443–455
T1/2 after the last dose in healthy volunteers Levodopa t1/2
after the last dose was longer after LCE treatment in all
groups. Mean (SD) levodopa t1/2 in groups I and II were 1.3
(0.20) and 1.4 (0.17) h, respectively, following LC
treatment, and 2.0 (0.37) and 1.9 (0.23) h, respectively,
following LCE treatment (P<0.001). Similarly, mean
levodopa t1/2 in groups III and IV were 1.6 (0.64) and 2.1
(1.2) h, respectively, following LC treatment, and 2.5 (1.2)
and 3.0 (1.4) h, respectively, following LCE treatment (P<
0.05 and P=0.25, respectively).
T1/2 after the last dose in PD patients Levodopa t1/2 after
the last dose was longer after LCE treatment in both groups.
Mean (SD) levodopa t1/2 in groups I and II were 1.3 (0.20)
and 1.4 (0.17) h, respectively, following LC treatment, and
2.0 (0.37) and 1.9 (0.23) h, respectively, following LCE
treatment (P<0.001).
Tmax in healthy volunteers In all four groups, median tmax
occurred at 0.5–1.0 h and 1.5 h after the first doses of LC and
LCE, respectively. After the second dose, the median tmax
occurred at 1.0–1.5 h with LC and 1.5–2.0 h with LCE.
Median tmax was usually observed at 1.5 h for latter doses of
both LC and LCE.
Tmax in PD patients Median tmax was 1.5 h after all doses of
LCE in both groups. With LC, the median tmax was 0.5 h
after the first dose and 1.5 h after the next doses.
Carbidopa
In healthy volunteers There was no statistically significant
difference between LCE and LC in terms of AUC covering
the entire day (AUC0–14 or AUC0–15) in any of the groups.
However, after the first dose of study treatment, AUCtau
values were 15–28% lower (P<0.05) with LCE compared
with LC in groups I, III, and IV (data not shown).
In PD patients There were no statistically significant
differences in carbidopa AUC0–14 between LCE and LC
treatments in groups I and II. All AUCtau values for each
dosing interval during 0–14 h were statistically nonsignif-
icant between the treatments. The only exception was
Table 6 Variability in levodopa concentrations throughout the day and during each dosing interval as assessed by Cmax−Cmin (ng/ml) in healthy
volunteers and patients with PD (groups I–II)
Dosing group and regimen LCE, mean (SD) LC, mean (SD) Ratio LCE/LCa P value
Healthy volunteers Group I: 100 mg × 4,
3.5-h interval, LCE n=9,
LC n=10
Mean Cmax−Cmin 949 (546) 949 (423) 0.89 0.24b
Cmax−Cmin (dose 1) 780 (415) 984 (343) 0.71 0.08
Cmax−Cmin (dose 2) 1,460 (565) 1,050 (570) 1.43 0.07
Cmax−Cmin (dose 3) 886 (539) 884 (373) 0.85 0.39
Cmax−Cmin (dose 4) 671 (324) 867 (412) 0.74 0.14
Group II: 150 mg × 4,
3.5-h interval, LCE n=10,
LC n=10
Mean Cmax−Cmin 1,420 (787) 1,460 (684) 0.92 0.51b
Cmax−Cmin (dose 1) 1,050 (373) 1,500 (866) 0.76 0.14
Cmax−Cmin (dose 2) 2,290 (625) 1,870 (622) 1.26 0.23
Cmax−Cmin (dose 3) 1,370 (568) 1,240 (510) 1.08 0.70
Cmax−Cmin (dose 4) 952 (774) 1,220 (565) 0.71 0.09
Patients with PD Group I: 100 mg × 4,
3.5-h interval, LCE n=10,
LC n=10
Mean Cmax−Cmin 824 (210) 978 (156) 0.82 <0.05b
Cmax−Cmin (dose 1) 770 (161) 951 (326) 0.84 0.21
Cmax−Cmin (dose 2) 875 (299) 999 (341) 0.84 0.21
Cmax−Cmin (dose 3) 870 (508) 1,030 (229) 0.75 <0.05
Cmax−Cmin (dose 4) 782 (335) 929 (285) 0.83 0.17
Group II: 150 mg × 4,
3.5-h interval, LCE n=9,
LC n=9
Mean Cmax−Cmin 1,350 (634) 1,490 (580) 0.92 0.48b
Cmax−Cmin (dose 1) 1,280 (735) 1,530 (989) 0.78 0.25
Cmax−Cmin (dose 2) 1,590 (595) 1,990 (421) 0.73 0.15
Cmax−Cmin (dose 3) 1,340 (973) 1,160 (779) 1.19 0.44
Cmax−Cmin (dose 4) 1,170 (783) 1,260 (781) 1.08 0.75
Cmax – Cmin Fluctuation in levodopa concentration, LCE levodopa/carbidopa/entacapone, LC levodopa/carbidopa, SD standard deviation, PD
Parkinson’s disease
a Ratio for estimates of geometric means
bP value was obtained by analyzing all individual values during 0–14 h
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AUCtau after the first dose in group II, which was
significantly lower with LCE compared to LC (P<0.01,
data not shown).
Entacapone concentrations
In healthy volunteers and PD patients In subjects treated
with LCE in period 1 (sequence “LCE-LC”), all entacapone
concentrations before the first dose of LC on the PK
assessment day of period 2 were below the quantification
limit of 10 ng/ml.
Safety
In healthy volunteers, the most common AEs reported during
the study period were nausea, chromaturia, headache,
vomiting, and dizziness. These occurred during LCE and/or
LC treatments. The frequency and intensity of nausea and
vomiting were higher with higher doses of study drugs.
In PD patients, most commonAEs during the study periods
were tremor, dizziness, headache, nausea, and chromaturia
occurring during LC and/or LCE treatments. Nausea was
clearly less common compared to healthy volunteers.
Vital signs and ECG data indicated no safety concerns
during the study, and there were no consistent differences
between LCE and LC treatment in this respect.
Discussion
This study was primarily designed to compare the levodopa
concentration profiles throughout the day with the specific
daily-dosing regimens of LCE and LC [100 or 150 mg of
levodopa four times daily (q.i.d.) at 3.5-h intervals] that are
used as the maintenance dose levels in a long-term clinical
study comparing LCE and LC in the treatment of early PD [17].
In the present study, t1/2 of levodopa (measured after the
last dose of the day) was longer after LCE administration in
all groups compared to LC. Due to prolonged t1/2 of
levodopa, both in healthy volunteers and PD patients, mean
trough levels (Cmin), maximum observed concentrations
(Cmax), and AUC values of levodopa were, in general,
significantly higher throughout the day during LCE
compared to LC administration. This was seen after all
dosing regimens regardless of the dose strength, number of
doses, or the dosing interval used. The biggest increases in
levodopa PK variables after LCE were generally seen in
Cmin and AUC, the mean increases ranging from approx-
imately 1.3-fold (AUC in groups I–II) to 2.0-fold (Cmin in
groups III–IV in healthy volunteers) compared to LC. In
turn, Cmax of levodopa was 1.1- to 1.3-fold higher after
LCE compared to LC in all groups. There were no
differences in the Cmax of levodopa between LCE and LC
after the first morning dose. This agrees with earlier studies
conducted in healthy subjects [2] and patients with PD [5],
which have shown that a single administration of LC and
entacapone does not increase the Cmax of levodopa. With
different dosing regimens, similar kinds of results (regard-
ing t1/2, Cmin, Cmax, and AUC of levodopa) have been
reported with repeated dosing of entacapone administered
together with standard release levodopa/carbidopa [4–5] or
with controlled-release levodopa/carbidopa [18]. It has also
been reported that co-administration of tolcapone t.i.d. with
four daily doses of levodopa/benserazide has significantly
increased Cmin, Cmax, and AUC of levodopa by up to 2- to
3-fold compared to levodopa/benserazide alone [20].
As seen from daily plasma level curves (Figs. 2 and 3),
levodopa concentrations tended to accumulate with both
treatments towards the end of the day. These results are well
in line with phase III results in patients with PD experiencing
wearing-off, showing that increases in on-time with levodopa/
dopa-decarboxylase inhibitor (DDCI) and entacapone therapy
were more pronounced towards the end of the day [7]. In
contrast to the pharmacokinetic parameters above, no signif-
icant differences were generally seen in variability (Cmax−
Cmin) of levodopa concentrations during the day between
LCE and LC, although there was a slight trend towards lower
variability (by 8–16%) with LCE during all dosing regimens.
It is well known that there is a relatively large
interindividual variability in levodopa absorption. There
are many possible explanations for this, for example,
different rates of gastric emptying [21]. However, our study
demonstrated that PK of levodopa in PD patients can be
predicted reasonably well based on results obtained from
healthy volunteers. This was especially true for relative
differences between the two levodopa formulations, but
also the absolute levodopa plasma levels in groups I and II
were close to each other between healthy volunteers and
PD patients. This adds to the previous literature reporting
that there are generally no differences in PK of levodopa
between de novo PD patients, patients with wearing-off
symptoms, or patients with late-stage disease [22].
Carbidopa concentration profiles were generally similar
between LCE and LC throughout the day in the present
study, i.e., entacapone did not affect carbidopa absorption
and plasma concentrations in any clinically significant way
during repeated dosing. The lack of quantifiable levels of
entacapone prior to the first LC dose on the PK assessment
day of period 2 in subjects who received LCE in period 1
ruled out carry-over effects from prior LCE treatment. As
entacapone has been in clinical use for approximately
10 years already, our focus was not to study COMT-
inhibition in detail. Therefore, no data on 3-OMD or other
metabolites of levodopa or dopamine are reported.
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The concept of continuous dopaminergic stimulation
(CDS) suggests that a more stable plasma concentration of
a given dopaminergic drug will result in a more continuous
response to treatment with decreased incidence of motor
complications [13]. It has also been claimed that maintain-
ing plasma levodopa concentrations above a minimum
antiparkinsonian threshold by avoiding low trough concen-
trations (Cmin) may be a key factor in optimizing treatment
response and reducing motor complications [15]. However,
in later-stage patients with wearing-off symptoms with or
without existing dyskinesia, enhancing dopaminergic ther-
apy with any oral medication will often increase dyskinesia
Fig. 2 Levodopa plasma concentration curves throughout the day for 16 h in healthy volunteers and patients with PD (groups I–II)
Fig. 3 Levodopa plasma concentration curves throughout the day for 17 h in healthy volunteers (groups III–IV)
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to some extent in addition to expected antiparkinsonian
effects. This is true also for enhancement of levodopa
therapy with COMT-inhibitors [7, 10, 23–24].
In early (or de novo) PD without wearing-off symptoms
and any dyskinesia, the situation may be different. So far
there is only experimental evidence showing that, in de
novo non-primed MPTP primates, treatment with LC and
entacapone (compared to LC alone) induced less dyskinesia
despite improving motor symptoms [16]. If the Cmin was
the most important PK variable of levodopa for reducing
the occurrence of motor complications in early PD, then
LCE would better fulfil this criterion compared to LC.
However, it is not known whether Cmin levels of levodopa
in this study were high enough in this respect even with
LCE. On the other hand, if significant difference in the
variability of levodopa concentrations (Cmax−Cmin) was the
key factor (regardless of the level at which this variability
occurs), then the present study might support that there will
be no significant difference in inducing motor complica-
tions between LCE and LC in early PD. The role of Cmax
levels of a given drug in CDS also remains unclear.
However, a recent study (in later-stage patients) suggested
that it may be more important to avoid low trough levels of
levodopa rather than to avoid higher Cmax levels [15].
In conclusion, the results of this study demonstrated
that 100 or 150 mg of LCE administered four to five
times daily at 3.0- to 3.5-h intervals provides a PK
profile with higher Cmin, Cmax, and AUC of levodopa
compared to LC. No unexpected tolerability issues were
seen in any of the study groups. The avoidance of low
troughs in plasma levodopa levels has been suggested to
be one of the most important factors resulting in better
symptomatic control of PD symptoms and delay in the
development of treatment-associated motor complications.
Whether the observed differences in trough levels and/or
other PK variables of levodopa in this study translate into
the delayed onset of motor complications in patients with
early PD remains to be seen. The double-blind, random-
ized, controlled, multicenter, long-term study [17] com-
paring LCE and LC q.i.d. in early PD may provide an
answer to this important question.
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